查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1649508

中枢早熟症(Cpp) 治疗市场：预测（2025-2030 年）

Central Precocious Puberty (Cpp) Treatment Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 143 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

中枢早熟症(Cpp) 治疗市场预计将从 2025 年的 16,348.72 亿美元成长到 2030 年的 23,848.72 亿美元，复合年增长率为 7.84%。

中枢早熟症(Cpp) 治疗涉及药物治疗，旨在管理和延缓因下丘脑-垂体-性腺 (HPG) 轴过早激活而导致的早熟症。性早熟的定义是女孩在8岁前、男孩在9岁前出现第二性征。主要治疗方法是使用促性腺激素分泌释放激素 (GnRH)促效剂，阻止性激素的分泌并减缓或阻止青春期的进程。药物治疗会延迟成熟，在某些情况下可以考虑手术。血液检查、MRI、 电脑断层扫描和X光等诊断工具可以帮助确定是否需要治疗。男性和女性均可接受治疗方法，主要在医院、专科诊所、居家照护机构和其他医疗机构进行。

中枢早熟症(Cpp) 治疗市场驱动因素

  • 荷尔蒙失调盛行率不断上升：荷尔蒙失调盛行率不断上升预计将在未来几年显着推动 CPP 治疗市场的成长。荷尔蒙失调包括体内荷尔蒙失衡而引起的多种病症。现代生活方式、环境暴露以及遗传或表观遗传因素导致这些疾病的盛行率不断上升。治疗 CPP 的主要目标是透过抑制触发青春期的讯号来控制荷尔蒙失衡引起的早熟症。因此，荷尔蒙异常发生率的增加是推动CPP治疗市场发展的关键因素。

地理视角

  • 亚太地区快速成长：亚太地区对 CPP 治疗的需求大幅增长，并且随着人们认识的提高、医疗保健系统的改善和疾病盛行率的上升，预计还将继续增长。诊断能力的提高、家长和医疗保健专业人员意识的增强以及潜在的环境影响都促成了这一趋势。都市化和生活方式的改变改变了人们的饮食习惯，增加了人们接触内分泌干扰物质的机会，这可能导致早熟症。宣传宣传活动和教育计划在鼓励儿童早期诊断和治疗 CPP 方面也发挥着重要作用。

为什么要购买这份报告？

  • 深刻分析：获得深入的市场洞察，涵盖主要和新兴地区，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透率。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中开闢新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问公司、中小企业和大型企业都有益且具有成本效益。

它有什么用途？

产业与市场分析、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

研究范围

  • 2022 年至 2030 年的实际资料和预测
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争定位、策略与市场占有率分析
  • 各细分市场及各地区（包括国家）的收益成长及预测分析
  • 公司概况（策略、产品、财务、主要发展等）

目录

第 1 章 简介

  • 市场概况
  • 市场定义
  • 研究范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 研究过程

第三章执行摘要

  • 主要发现
  • CXO观点

第四章 市场动态

  • 市场驱动因素
  • 市场限制
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

5. 中枢早熟症(Cpp) 治疗市场（依药物类型）

  • 介绍
  • 亮丙瑞林
  • 希斯特兰
  • 曲普瑞林
  • 那法瑞林

6. 中枢性早熟症(Cpp) 治疗市场依通路划分

  • 介绍
  • 医院
  • 零售
  • 在线的

7. 中枢早熟症(Cpp) 治疗市场（按地区）

  • 介绍
  • 北美洲
    • 依药物类型
    • 按分销管道
    • 按国家
  • 南美洲
    • 按类型
    • 按最终用户产业
    • 按国家
  • 欧洲
    • 依药物类型
    • 按分销管道
    • 按国家
  • 中东和非洲
    • 依药物类型
    • 按分销管道
    • 按国家
  • 亚太地区
    • 依药物类型
    • 按分销管道
    • 按国家

第八章 竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争仪錶板

第九章 公司简介

  • Pfizer Inc
  • AbbVie Inc
  • Sanofi
  • GlaxoSmithKline plc
  • Novartis AG
  • F Hoffmann-La Roche Ltd
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd
  • Ipsen Pharma
  • Arbor Pharmaceuticals.
  • Mylan NV
  • Arbor Pharmaceuticals
  • Tolmar Pharmaceuticals, Inc.
  • GP Pharm
  • DAEWOONG PHARMACEUTICAL CO LTD
  • Sun Pharmaceutical Industries Ltd.
简介目录
Product Code: KSI061617273

The Central Precocious Puberty (CPP) treatment market is expected to grow at a CAGR of 7.84%, reaching a market size of US$2,384.872 million in 2030 from US$1,634.872 million in 2025.

Central precocious puberty (CPP) treatment involves medicinal therapies aimed at managing and delaying the premature onset of puberty due to early activation of the hypothalamic-pituitary-gonadal (HPG) axis. Precocious sexual maturation is defined as the emergence of secondary sexual characteristics before the age of eight in girls and nine in boys. The primary approach to treatment utilizes gonadotropin-releasing hormone (GnRH) agonists, which inhibit the initiation of sex hormones and slow or halt the progression of puberty.Treatment for CPP can be either medicinal or surgical, depending on individual cases. Therapies are designed to postpone maturation, while surgery may be considered in specific situations. Diagnostic tools such as blood tests, MRIs, CT scans, and X-rays assist in determining the necessity for treatment. The therapies are available for both boys and girls and are primarily administered in hospitals, specialized clinics, home care settings, and other healthcare facilities.

Drivers of the Central Precocious Puberty (CPP) Treatment Market

  • Increasing Prevalence of Hormonal Disorders: The rising incidence of hormonal disorders is expected to significantly drive the growth of the CPP treatment market in the coming years. Hormonal disorders encompass a range of medical conditions resulting from hormonal imbalances within the body. Modern lifestyles, environmental exposures, and genetic or epigenetic factors contribute to the increasing prevalence of these disorders. The primary goal of CPP treatment is to manage early-onset puberty caused by hormonal imbalances by suppressing the signals that trigger puberty. Therefore, the growing incidence of hormonal abnormalities is a key factor propelling the CPP treatment market.

Geographical Outlook

  • Exponential Growth in Asia Pacific: The demand for CPP therapy in the Asia-Pacific region is growing impressively, with expectations for continued growth driven by increased awareness, improved healthcare systems, and a higher prevalence of the disorder. Enhanced diagnostic capabilities, greater awareness among parents and healthcare professionals, and potential environmental influences have contributed to this trend. Urbanization and lifestyle changes have altered diets and increased exposure to endocrine-disrupting substances that may lead to early puberty. Awareness campaigns and educational programs have also played a significant role in encouraging early diagnosis and treatment for CPP among children.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Central Precocious Puberty (CPP) treatment market is segmented and analyzed as follows:

By Drug Type

  • Leuprorelin
  • Histrein
  • Triptorelin
  • Nafarelin

By Distribution Channel

  • Hospitals
  • Retail
  • Online

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Indonesia
  • Taiwan
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET BY DRUG TYPE

  • 5.1. Introduction
  • 5.2. Leuprorelin
  • 5.3. Histrein
  • 5.4. Triptorelin
  • 5.5. Nafarelin

6. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET BY DISTRIBUTION CHANNEL

  • 6.1. Introduction
  • 6.2. Hospitals
  • 6.3. Retail
  • 6.4. Online

7. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Drug Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
      • 7.2.3.1. USA
      • 7.2.3.2. Canada
      • 7.2.3.3. Mexico
  • 7.3. South America
    • 7.3.1. By Type
    • 7.3.2. By End-User Industry
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
      • 7.3.3.2. Argentina
      • 7.3.3.3. Others
  • 7.4. Europe
    • 7.4.1. By Drug Type
    • 7.4.2. By Distribution Channel
    • 7.4.3. By Country
      • 7.4.3.1. Germany
      • 7.4.3.2. France
      • 7.4.3.3. United Kingdom
      • 7.4.3.4. Italy
      • 7.4.3.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. By Drug Type
    • 7.5.2. By Distribution Channel
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
      • 7.5.3.2. Israel
      • 7.5.3.3. UAE
      • 7.5.3.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. By Drug Type
    • 7.6.2. By Distribution Channel
    • 7.6.3. By Country
      • 7.6.3.1. China
      • 7.6.3.2. Japan
      • 7.6.3.3. South Korea
      • 7.6.3.4. India
      • 7.6.3.5. Indonesia
      • 7.6.3.6. Taiwan
      • 7.6.3.7. Thailand
      • 7.6.3.8. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Pfizer Inc
  • 9.2. AbbVie Inc
  • 9.3. Sanofi
  • 9.4. GlaxoSmithKline plc
  • 9.5. Novartis AG
  • 9.6. F Hoffmann-La Roche Ltd
  • 9.7. Mylan N.V.
  • 9.8. Teva Pharmaceutical Industries Ltd
  • 9.9. Ipsen Pharma
  • 9.10. Arbor Pharmaceuticals.
  • 9.11. Mylan N.V.
  • 9.12. Arbor Pharmaceuticals
  • 9.13. Tolmar Pharmaceuticals, Inc.
  • 9.14. GP Pharm
  • 9.15. DAEWOONG PHARMACEUTICAL CO LTD
  • 9.16. Sun Pharmaceutical Industries Ltd.